about
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystalsRIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells.ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.Immunotherapy in Tumors.A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing miceStrategies to relieve immunosuppression in pancreatic cancer.Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer.Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity.Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model.An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma.Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma.Breaking tumor-induced immunosuppression with 5'-triphosphate siRNA silencing TGFβ and activating RIG-I.Induction of immunogenic cell death by targeting RIG-I-like helicases in pancreatic cancer.Assessment and quantification of crystal-induced lysosomal damage.Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer.RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8+ T cells.P17. RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells.Volcanic Ash Activates the NLRP3 Inflammasome in Murine and Human Macrophages.Western Diet Triggers NLRP3-Dependent Innate Immune Reprogramming.Nlrp3-dependent IL-1β inhibits CD103+ dendritic cell differentiation in the gut.Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies.P10. Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8+ T cell and B cell responses but improves clinical efficacy in a murine pancreatic carcinoma model.Microphthalmia-Associated Transcription Factor (MITF) Regulates Immune Cell Migration into MelanomaColitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasomeProtective and aggravating effects of Nlrp3 inflammasome activation in IBD models: influence of genetic and environmental factorsInflammasome-dependent and -independent IL-18 production mediates immunity to the ISCOMATRIX adjuvantImmunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancerRIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockadePD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin LymphomaNLRP3 inflammasome activation in inflammagingHigh-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapySystemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model
P50
Q29615704-07613CFD-546D-48EC-8AA2-09A595F73A37Q34486464-A4EE6AB2-4117-494D-88F6-1CDEEC51103AQ34848159-C547A4AA-521A-439A-9D23-3978F360A034Q36453637-F24AB368-0809-4156-8A62-3A97AECDC315Q37222176-9928FA4A-4DEE-4802-8977-6C1E30D5F0FAQ38445328-6A7D5055-5F43-45DA-9D28-A5D0818690EDQ38770259-17F3C529-E0BB-41C6-99BE-5CDC2F9CDAA2Q38902246-22A93F07-A0CF-4878-80EA-A5423BF84EB4Q39037817-D2FB01B1-138D-4401-9284-35BF565AEF97Q39703281-95F0666B-F2C6-4A83-AB05-83D847129E58Q41182217-783005B6-BCA1-4E16-BF6D-E4C6FE024B8DQ41219698-022DB64D-A565-4F52-B6DE-90F76715C1E3Q41857672-48DB6AD8-A804-4980-9487-682ACC8E8FC4Q43459622-D61E2770-7B51-43C0-BF2F-E96EFA40FF9CQ44133324-AA7D734D-F6DC-44A3-892D-0255C47B410CQ45835225-3AEF41D8-6A85-4EB4-9C23-616F2D00D15AQ47156404-9C32CA01-9F37-4825-A74C-330E87D5040EQ49191081-4E12FF5F-1BF1-4F87-8B9E-B6BC43C33182Q50065321-38305793-9DB1-463E-9BEA-E134D1AB8A2CQ52728109-0B0F6DA5-D507-43B8-9590-CC4B4971098DQ55405466-533772FD-B87A-4156-B759-681177A0EA38Q55545484-7589D925-AFB4-44EF-BC3B-DEBC929A1654Q60311076-7CBEC628-FF67-4E65-868D-D3D2AFAFD569Q84155882-E186F852-85AE-480C-90AD-877BFEB0AFC1Q85213695-E9312EEF-3543-4D68-8DBD-A59B04C3BA8DQ87416334-7CFEDA60-3E46-42B2-B710-18EC3345EC85Q91149770-EA64B243-4E09-48D3-B836-B300C7EFD6B8Q91330101-B876F09E-B7FD-4B61-90F1-7501501DDE18Q91438869-2C89643E-AA22-4594-A423-6EC2F725E89EQ91881801-23A0DA06-7DF0-4386-8B83-2716A20BBF4BQ93081052-5BC2DF2E-53E3-401C-965A-6A37FBE84A36Q95655631-0B91FC56-AA1C-40DF-9008-3423BE46C7A0
P50
description
researcher ORCID ID = 0000-0003-0836-6448
@en
wetenschapper
@nl
name
Peter Duewell
@ast
Peter Duewell
@en
Peter Duewell
@es
Peter Duewell
@nl
type
label
Peter Duewell
@ast
Peter Duewell
@en
Peter Duewell
@es
Peter Duewell
@nl
prefLabel
Peter Duewell
@ast
Peter Duewell
@en
Peter Duewell
@es
Peter Duewell
@nl
P106
P21
P31
P496
0000-0003-0836-6448